On Friday, Invesco Ltd. (NYSE:IVZ)’s shares declined -1.01% to $38.21.
Invesco Canada has declared a change to the risk rating on three of its funds.
The updated risk ratings provide investors with a more accurate description of the risk profiles they can expect from these three investment options. The new risk ratings do not reflect any changes to the investment objectives, investment strategies or administration of these funds.
Commissions, trailing commissions, administration fees and expenses may all be associated with mutual fund investments. Mutual funds are not guaranteed, their values change frequently and past performance may not be repeated. Please read the simplified prospectus before investing. Copies are accessible from your advisor or Invesco Canada Ltd.
Invesco Ltd. is a publicly owned investment manager. The firm provides its services to retail clients, institutional clients, high-net worth clients, public entities, corporations, unions, non-profit organizations, endowments, foundations, pension funds, financial institutions, and sovereign wealth funds. It manages separate client focused equity, balanced, and fixed income portfolios. The firm also launches equity, fixed income, commodity, multi-asset, and balanced mutual funds for its clients.
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)’s shares gained 7.16% to $7.48.
Spectrum Pharmaceuticals, Inc. ( SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, declared recently financial results for the three-month period ended June 30, 2015.
Pipeline Update:
Two Potential Blockbusters, One Near-term FDA Decision and One Near-term NDA Submission
- SPI-2012, a novel long-acting GCSF: In Phase 2 trials earlier this year, SPI-2012’s efficacy was shown to be non-inferior at the middle dose, and superior to the blockbuster drug pegfilgrastim at the higher dose tested. Based on talk aboution with the FDA, the Company plans to initiate a Phase 3 study this year, and is seeking an SPA for this study that would be powered at over 90% to demonstrate non-inferiority and at 80% to demonstrate superiority to pegfilgrastim.
- EVOMELA, a propylene-glycol free formulation of melphalan with improved stability: NDA review is ongoing and is on track for an FDA decision on October 23, 2015. This drug is predictable to be launched using Spectrum’s existing sales force, and pre-launch activities have commenced.
Spectrum Pharmaceuticals, Inc., a biotechnology company, develops and commercializes oncology and hematology drug products. The company markets five drug products, counting FUSILEV for the treatment of patients with metastatic colorectal cancer, rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL); ZEVALIN injection for patients with follicular non-Hodgkins lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation of the anticancer drug vincristine for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; and BELEODAQ injection for patients with relapsed or refractory PTCL.
At the end of Friday’s trade, Berry Plastics Group Inc (NYSE:BERY)‘s shares surged 0.27% to $29.31.
Berry Plastics Group, Inc. (BERY) stated results for its third fiscal 2015 quarter, referred to in the following as the June 2015 quarter:
- Raised cash flow from operations by 50 percent to $180 million in the June 2015 quarter contrast to $120 million in the same preceding year quarter.
- Recorded net loss per diluted share of $0.11 and adjusted net income per diluted share of $0.51 for the June 2015 quarter.
- Raised operating EBITDA to $219 million (17.6 percent margin) for the June 2015 quarter contrast to $212 million (16.3 percent margin) in the same preceding year quarter.
- Improved adjusted free cash flow by $74 million to $140 million for the June 2015 quarter contrast to $66 million in the same preceding year quarter.
- Generated adjusted free cash flow of $378 million and adjusted EBITDA of $830 million for the four quarters ended June 2015.
- Raised fiscal 2015 adjusted free cash flow guidance to $400 million.
Berry Plastics Group, Inc. manufactures and distributes plastic consumer packaging and engineered materials in North America and internationally. The company operates through four segments: Rigid Open Top, Rigid Closed Top, Engineered Materials, and Flexible Packaging.
Outfront Media Inc (NYSE:OUT), ended its Friday’s trading session with -5.40% loss, and closed at $23.65.
OUTFRONT Media Inc. (OUT) declared that its board of directors has approved a quarterly cash dividend on the Company’s stock of $0.34 per share payable on September 30, 2015 to shareholders of record at the close of business on September 10, 2015.
OUTFRONT Media Inc. provides advertising space on out-of-home advertising structures and sites in the United States, Canada, and Latin America. Its portfolio primarily comprises of billboard displays, which are principally located on the heavily traveled highways and roadways; and transit advertising displays with multi-year contracts with municipalities in various cities across the United States.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
